Increased Bcl-2 expression is associated with poor survival in B-cell chronic lymphocytic leukemia (CLL), prostate cancer and urinary tract transitional cell cancer [6-9]; while its high expression is associated to favorable outcome in colorectal cancer, breast cancer, non-small-cell lung cancer, renal cancer and head and neck cancer [10-15]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.